Allergan PLC. (AGN) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group cut its stake in shares of Allergan PLC. (NYSE:AGN) by 1.0% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 413,952 shares of the company’s stock after selling 3,996 shares during the period. Schroder Investment Management Group owned about 0.12% of Allergan PLC. worth $101,012,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Honeywell International Inc. raised its position in Allergan PLC. by 13.6% during the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after acquiring an additional 20,100 shares during the period. Israel Discount Bank of New York acquired a new position in Allergan PLC. during the first quarter worth $988,000. Palladium Partners LLC raised its position in Allergan PLC. by 1.7% during the second quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after acquiring an additional 523 shares during the period. Trust Co. of Vermont raised its position in Allergan PLC. by 62.8% during the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after acquiring an additional 1,109 shares during the period. Finally, DekaBank Deutsche Girozentrale acquired a new position in Allergan PLC. during the second quarter worth $41,345,000. Institutional investors own 82.02% of the company’s stock.

Shares of Allergan PLC. (NYSE:AGN) opened at 204.65 on Monday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market capitalization of $68.42 billion, a PE ratio of 6.24 and a beta of 1.18. The company’s 50-day moving average is $229.79 and its 200 day moving average is $236.07.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the company posted $3.35 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts expect that Allergan PLC. will post $16.26 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.37%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

A number of research firms have weighed in on AGN. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a research report on Monday, June 26th. Wells Fargo & Company restated an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. UBS AG restated an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a research report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and set a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Sunday, July 16th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $273.34.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/09/25/allergan-plc-agn-shares-sold-by-schroder-investment-management-group.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply